No Data
Concept mining | Simgeglutide weight loss drug officially launched in China, multiple e-commerce platforms have gone online
The market has broad prospects
Shengnuo Biotech: Third Quarter Report 2024
Third Quarter Report 2024
ChengDu ShengNuo Biotec's Nine-Month Profit Seen to Surge Up to 76%
VOLUNTARY DISCLOSURE ANNOUNCEMENT FOR THE FIRST THREE QUARTERS OF 2024
Another one! Peptide products drive 'hot' performance, Sanuo Biological's net profit for the first three quarters is expected to increase by 76%.
①Peptide active pharmaceutical ingredients and formulation products are selling well, driving Shen Nuo Biotech's net income in the first three quarters to reach as high as 61.1987 million yuan, with the highest year-on-year increase of 75.88%. ②In September of this year, Shen Nuo Biotech signed a GLP-1 peptide active pharmaceutical ingredient supply contract worth up to 0.35 billion yuan, with a performance period until December 31, 2025.
What ChengDu ShengNuo Biotec Co.,Ltd.'s (SHSE:688117) 30% Share Price Gain Is Not Telling YouNo Data
No Data
